摘要 |
This invention provides a novel class of androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds which are tissue-selective androgen receptor modulators (SARM), which are useful for oral testosterone replacement therapy, male contraception, maintaining sexual desire in women, treating prostate cancer and imaging prostate cancer. The SARM compounds are represented by general formula I:wherein X is O, Z is NO, COR, COOH or CONHR; Y is I, CF, Br, Cl, or Sn(R); Q is alkyl, halogen, N(R), NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH, NHCSCF, NHCSR, NHSOCH, NHSOR, OR, COR, OCOR, OSOR, SOR or SR wherein Ris an alkyl, aryl, Ris CH, CFCHCH, or CFCFand T is OH, OR,-NHCOCH, or NHCOR wherein R is a Calkyl, a Chaloalkyl, phenyl, halo, alkenyl or hydroxyl, wherein Q is not NHCOCHor NHCOCF. These agents have an unexpected in-vivo activity for an androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. These agents may be active alone or in combination with progestins or estrogens. The invention further provides a novel class of non-steroidal agonist compounds. The invention further provides compositions containing the selective androgen modulator compounds or the non-steroidal agonist compounds and methods of binding an androgen receptor, modulating spermatogenesis, treating and imaging prostate cancer, and providing hormonal therapy for androgen-dependent conditions. |